Andrew Chan, EAN 2020 – COVID-19 and Multiple Sclerosis

Great to catch-up with Andrew Chan (Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland), who discussed challenges posed to patient care by COVID-19, factors to consider around immunosuppression for patients with multiple sclerosis (MS) during the pandemic, as well his personal thoughts on exciting developments in MS therapy and the 1st Virtual EAN Congress.

Questions
1. What are the challenges posed to patient care by COVID-19? (0:05)
2. What are the main factors to consider when assessing the risks and benefits of immunosuppression for MS during the pandemic? (1:44)
3. What have been the most exciting developments in MS therapy over the past year? (4:10)
4. What did you enjoy most at year’s Virtual EAN Congress? (5:29)

Speaker disclosure: Andrew Chan has served on advisory boards for, and received funding for travel or speaker honoraria from, Actelion-Janssen, Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and Teva, all for hospital research funds; and research support from Biogen, Genzyme and UCB. Andrew Chan holds a patent relating to mTOR inhibition as a mechanism to increase glucocorticoid efficacy, is associate editor of the European Journal of Neurology and serves on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.